Skip to main content
CGTX
NASDAQ Life Sciences

FDA Meeting Clears Path for Zervimesine's Pivotal Study in Lewy Body Dementia Psychosis

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.21
Mkt Cap
$115.452M
52W Low
$0.222
52W High
$3.83
52W Position info
444% above low
Off High info
68% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

CGTX has more than doubled off its 52-week low of $0.222.

Summary

Cognition Therapeutics announced a positive meeting with the FDA, establishing a clear path forward for a registrational study of its lead drug zervimesine (CT1812) in dementia with Lewy bodies (DLB) with psychosis. This follows the company's March announcements about advancing zervimesine for DLB psychosis and compelling Phase 2 data. This regulatory clarity is a significant de-risking event for the company's lead candidate, outlining the pathway towards potential market approval. The company anticipates reviewing the FDA's formal minutes in June, which should provide further details on the registrational program design.

At the time of this announcement, CGTX was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.5M. The 52-week trading range was $0.22 to $3.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CGTX - Latest Insights

CGTX
Nov 05, 2026, 6:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.6833
Real-time Price: $0.5915 info
Change: -$0.0918 (-13%) info
Market Cap: $57.118M info
CGTX
Nov 05, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6833
Real-time Price: $0.5915 info
Change: -$0.0918 (-13%) info
Market Cap: $57.118M info
CGTX
Oct 22, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.5915 info
Change: -$0.2085 (-26%) info
Market Cap: $57.118M info
CGTX
Oct 22, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7995
Real-time Price: $0.5915 info
Change: -$0.208 (-26%) info
Market Cap: $57.118M info
CGTX
Oct 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.865
Real-time Price: $0.5915 info
Change: -$0.2735 (-32%) info
Market Cap: $57.118M info